Alopecia Areata in 2 Patients Treated with Dupilumab: New Onset and Worsening

    August 2019 in “ JAAD Case Reports
    Janice Chung, Christa Slaught, Eric L. Simpson
    Image of study
    TLDR Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.
    The document reports two cases where patients with atopic dermatitis (AD) treated with dupilumab experienced changes in their alopecia areata (AA) condition—one with new onset and subsequent improvement of alopecia universalis (AU), and the other with worsening of previously diagnosed alopecia totalis (AT). In the first case, a 51-year-old woman with lifelong AD experienced generalized hair thinning after 26 months of dupilumab treatment, which progressed to AA and then to AU. Despite this, after resuming regular monthly dosing of dupilumab, she experienced dramatic hair regrowth, with 90% scalp regrowth after 10 months. In the second case, a 25-year-old man with severe AD and AT experienced complete loss of his remaining patches of hair after 6 to 8 weeks of dupilumab treatment. His condition did not improve with dupilumab, but he saw improvement with tofacitinib. The document concludes that while dupilumab can provide significant relief for AD, its effects on AA are unclear and can potentially impact the patient's quality of life and self-esteem. Therefore, it is necessary to discuss the possibility of new-onset or exacerbation of AA when considering dupilumab treatment for AD.
    Discuss this study in the Community →

    Cited in this study

    4 / 4 results

    Related

    5 / 5 results